Opendata, web and dolomites

UNPACK PD-L1 SIGNED

Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UNPACK PD-L1 project word cloud

Explore the words cloud of the UNPACK PD-L1 project. It provides you a very rough idea of what is the project "UNPACK PD-L1" about.

types    exploited    uncover    extracellular    highlighting    pd    bracket    agents    tumorigenic    inhibiting    models    power    express    inhibit    clinical    efficacy    programmed    broaden    plasma    mechanisms    therapeutic    little    ligand    clear    herein    patients    suppress    death    reveal    l1    cancer    oncological    meant    therapy    groundwork    outcome    limited    receptor    melanoma    responders    drug    cell    remove    initiated    clinically    center    stratify    guide    optical    release    pro    direction    stage    bioluminescent    upregulation    secretion    mechanism    therapies    responder    mediated    suppression    levels    secrete    checkpoint    inhibitors    surround    molecular    anti    immune    vitro    basic    sought    bottlenecks    ideally    screen    membrane    small    restore    intend    lay    druggable    reporters    tumor    loading    harnessing    subsequent    inhibition    ev    systemic    treat    function    circulating    modality    drive    strategy    tested    gaps    cells    blockade    unanticipated    evs    combining    tumour    plausible    candidates    immunosuppression    vesicles    rationale    mouse    successful    block   

Project "UNPACK PD-L1" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 175˙572 €
 EC max contribution 175˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 175˙572.00

Map

 Project objective

Harnessing the power of the immune system to treat cancer has long been a sought after goal of oncological research. Immune checkpoint inhibitors, such as anti-programmed death receptor 1 (PD-1) blockade therapies, have now taken center stage. However not all patients respond, highlighting gaps in our understanding of the mechanisms of tumour immunosuppression. Upregulation of the PD-1 ligand (PD-L1) on tumour cells initiated this therapeutic direction, yet it is becoming clear that the modality of PD-L1-mediated immune suppression is not limited to the plasma membrane. Like many tumor cells, melanoma cells secrete small extracellular vesicles (EVs) with pro-tumorigenic properties. Melanoma EVs express PD-L1 that suppress T cell function and facilitate tumour growth in pre-clinical mouse models. This systemic mechanism is clinically relevant, as circulating EV-PD-L1 levels can stratify anti-PD-1 clinical responders from non-responders. Thus inhibiting EV-PD-L1 may increase anti-PD-1 efficacy and broaden the responder bracket. One plausible strategy would be to block tumor EV secretion, yet little is known about the molecular mechanisms that drive PD-L1 loading and release. Herein, I intend to uncover the molecular mechanisms of EV PD-L1 release from melanoma cells using state-of-the-art optical and bioluminescent reporters to reveal novel druggable targets. This basic knowledge will be exploited to guide subsequent inhibition, through a drug screen for candidates that inhibit EV-PD-L1 release and restore T cell function. Ideally the outcome of this in vitro study will provide a strong rationale for combining anti-PD-1 agents with inhibitors of EV-PD-L1 secretion, to be tested in pre-clinical mouse models. If successful, melanoma EV blockade may remove the unanticipated bottlenecks that surround the efficacy of anti-PD-1 therapy. In the long term this study is meant to lay groundwork for tumor EV inhibition as a therapeutic strategy for cancer types beyond melanoma.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNPACK PD-L1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNPACK PD-L1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Drought (2020)

Drought coping strategies in southern Africa 1966-2016

Read More  

POSPORI (2019)

Polymer Optical Sensors for Prolonged Overseeing the Robustness of civil Infrastructures

Read More  

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More